Faith E. Davies

Research interests

Publications

• International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

  Journal of Clinical Oncology · 2025 · https://doi.org/10.1200/jco-24-01893

• Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30756-7

• Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

  Blood · 2018 · https://doi.org/10.1182/blood-2018-03-840132

• Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30687-9

• A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

  Leukemia · 2018 · https://doi.org/10.1038/s41375-018-0196-8

• Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

  Nature Communications · 2017 · https://doi.org/10.1038/s41467-017-00296-y

• Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.59.1503

• APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

  Nature Communications · 2015 · 10.1038/ncomms7997

• Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.57.9961

• Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.46.2119

• Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.199

• The genetic architecture of multiple myeloma

  Nature reviews. Cancer · 2012 · https://doi.org/10.1038/nrc3257

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.196

• Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

  Blood · 2011 · https://doi.org/10.1182/blood-2011-06-358812

• The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

  Blood · 2011 · 10.1182/blood-2011-06-357038

• A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

  Leukemia · 2011 · 10.1038/leu.2011.204

• A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

  Blood · 2010 · https://doi.org/10.1182/blood-2010-04-279596

• First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)62051-x

• International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

  Leukemia · 2009 · https://doi.org/10.1038/leu.2009.174

• The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells

  Cancer Research · 2007 · 10.1158/0008-5472.can-06-4230

• Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.03.2086

• Genetics and Cytogenetics of Multiple Myeloma

  Cancer Research · 2004 · https://doi.org/10.1158/0008-5472.can-03-2876

• High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma

  New England Journal of Medicine · 2003 · https://doi.org/10.1056/nejmoa022340

• Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

  Blood · 2002 · https://doi.org/10.1182/blood-2002-03-0996

• Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

  Leukemia · 2001 · https://doi.org/10.1038/sj.leu.2402295

• Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

  Blood · 2001 · https://doi.org/10.1182/blood.v98.1.210

• Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

  Blood · 2001 · https://doi.org/10.1182/blood.v98.2.428

• Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

  Blood · 2000 · https://doi.org/10.1182/blood.v96.9.2943

Current projects

No projects listed.